Insights into the pharmaceutical properties and in silico study of novel hydrazone derivatives.

阅读:3
作者:Ibraheem Hiba H, Queen Batool K, Al-Sabti Matheel D, Issa Ali A, Al-Majedy Yasameen K, Jabir Majid S, Sulaiman Ghassan M, Hasoon Buthenia A, Eshaq Merriam M, Jawad Kareem H, Jawad Sabrean F, Fawzi Hayder A, Shuaib Muhammad, Najm Mazin A A, Swelum Ayman A
It has been established that the Hydrazone derivatives have important pharmacological effects. In the first step, hydrazine (NH(2)NH(2)) reacts with a compound containing a carbonyl group (C = O) in the presence of ethanol and heat, leading to the formation of hydrazone compound (H1). The second step is the formation of the Schiff base (H2) by the reaction of compound (H1) with indole, ethanol, and acetic acid, which contain a double bond (C = N). In the third step, the (H1) reacts with thiophene, ethanol, and acetic acid to form a compound (H3) containing multiple bonds between the indole and thiophene rings. The synthetic test compounds underwent characterization using TLC, IR, 1 H - NMR, and ¹(3)C NMR spectral examinations. Both compounds, H2 and H3, exhibit antioxidant activity at different concentrations (from 12.5 to 100 µgmL(- 1)), where the effect increases gradually with the increase in concentration. The compounds (H2 and H3) exhibited an apparent inhibitory effect on the growth of Staphylococcus aureus, Escherichia coli, and Candida albicans. Calculations have been performed for DFT, molecular docking, molecular dynamics simulations, and the ADMET protocol, and they are essential for describing the interaction and stability. In hydrazone derivatives, groups like amine, hydroxy, thiophene, and indole form hydrogen bonds and electrostatic interactions with amino acids such as arginine, lysine, glutamic acid, and aspartic acid. These interactions are crucial to evaluating the compound's stability and its potential to inhibit enzyme activity. The results indicate that the compound shows strong binding and stability at the active site, making it a promising candidate for further studies as an anti-colon cancer agent.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。